Nantes hospital cooling system sparks controversy
Translated from French, summarized and contextualized by DistantNews.
At a glance
- Unions and politicians in Nantes, France, are concerned that the new CHU hospital's bioclimatic facades and cooling system will be less effective than traditional air conditioning.
- The hospital administration held a press conference to address concerns, stating the system is proven and uses cutting-edge design.
- Only essential areas like operating rooms and intensive care units will have traditional air conditioning; standard patient rooms will rely on the bioclimatic system and backup ventilation.
Concerns are mounting over the cooling system for Nantes's future CHU hospital, with unions and politicians questioning its efficacy compared to traditional air conditioning. The Loire Santรฉ hospital, scheduled to open in 2028, will only have half of its facilities fully air-conditioned.
Areas requiring strict temperature control, such as operating rooms, emergency departments, intensive care units, and laboratories, will be equipped with conventional air conditioning. However, standard patient hospitalization rooms will rely on a bioclimatic facade system for cooling. An air renewal system is also in place to provide additional cooling during heatwaves.
Amidst a heatwave, these concerns have intensified. In response, the CHU de Nantes administration organized a press conference titled "The truth about air conditioning and thermal comfort." They asserted that the bioclimatic system is not an untested innovation but a well-established technology with a proven track record.
The administration emphasized that the hospital will benefit from "cutting-edge design" in its thermal comfort solutions. This approach aims to balance patient well-being with energy efficiency, though critics remain skeptical about its performance during extreme weather conditions.
Originally published by Le Figaro in French. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.